FL3

FL3
Name	FL3
Caption	Structural representation of a flavagline derivative
Legal status	Investigational
Routes of administration	Intravenous; experimental oral formulations
Bioavailability	Variable; formulation-dependent
Metabolism	Hepatic; cytochrome P450–mediated pathways implicated
Elimination half-life	Species-dependent; reported in rodent studies

FL3

FL3 is a synthetic small molecule belonging to the flavagline family of natural product–inspired compounds. It was developed from lead compounds isolated from Aglaia species and has been investigated for potential anticancer, cardioprotective, and antiparasitic activities. Research on FL3 spans multidisciplinary efforts involving medicinal chemistry, translational oncology, and parasitology laboratories at academic institutions and biopharmaceutical companies.

Overview

FL3 is derived from the flavagline scaffold first reported in extracts of Aglaia odorata and related Meliaceae plants. The compound entered preclinical development after structure–activity relationship studies by groups at institutions such as CNRS, Institut Pasteur, and multiple university laboratories in Europe and North America. FL3 has been studied in models involving cell lines from breast cancer, prostate cancer, and pancreatic cancer, and in models of ischemia–reperfusion injury and Leishmania infection. Collaborative studies have included researchers affiliated with INSERM, Harvard Medical School, Johns Hopkins University, and biotech firms pursuing oncology therapeutics.

Chemical Structure and Properties

FL3 is a synthetic analogue of natural flavaglines characterized by a cyclopenta[b]benzofuran core fused to polycyclic substituents. Its structure incorporates stereochemical elements critical for biological activity, analogous to other members such as rocaglamide and silvestrol, originally reported in studies at Max Planck Institute and Scripps Research. Physicochemical properties include moderate lipophilicity, aromatic-rich topology, and hydrogen-bonding motifs that enable interaction with protein targets. Spectroscopic characterization has been reported using nuclear magnetic resonance at facilities like Bruker-equipped cores and mass spectrometric analyses at laboratories affiliated with Thermo Fisher Scientific instrumentation. Crystallographic or modeled conformations have been compared with crystal structures deposited by groups using synchrotron sources at facilities such as ESRF.

Mechanism of Action

Mechanistic studies indicate that FL3 targets components of the translational machinery and mitochondrial apoptotic regulators. Evidence from biochemical assays and proteomic studies implicates interactions with eukaryotic initiation factors analogous to interactions described for rocaglamide with eIF4A. FL3 has been reported to modulate the activity of heat shock protein 70 family members and to perturb actin-associated pathways, with downstream effects on BCL-2 family proteins and mitochondrial outer membrane permeabilization. Functional genomics and chemical biology efforts employing CRISPR screens at institutions such as Broad Institute and MIT have helped map genetic dependencies that sensitize cells to FL3, revealing context-specific vulnerabilities in models of KRAS-mutant pancreatic adenocarcinoma and triple-negative breast cancer.

Preclinical and Clinical Research

Preclinical efficacy has been demonstrated in xenograft models using cell lines from MCF-7, MDA-MB-231, PC3, and PANC-1 with tumor growth inhibition reported in multiple independent studies at research centers including Dana-Farber Cancer Institute and MD Anderson Cancer Center. FL3 has exhibited chemosensitizing effects in combination with agents such as doxorubicin, cisplatin, and targeted therapies including erlotinib in selected models. Cardioprotective activity was evaluated in ischemia models at cardiovascular research centers like Cleveland Clinic, showing preservation of mitochondrial function in preliminary studies. Antiparasitic activity against Leishmania donovani and other kinetoplastids was explored by parasitology groups at London School of Hygiene and Tropical Medicine and University of Oxford. As of latest reports, FL3 remains at the preclinical or early investigational stage with no registered phase II/III clinical trials at regulatory agencies such as FDA or EMA.

Synthesis and Derivatives

Synthetic routes to FL3 and analogues have been published by academic and industrial medicinal chemistry groups, building on methodologies developed for rocaglamide-type molecules by teams at ETH Zurich, University of California, Berkeley, and Shanghai Institute of Organic Chemistry. Strategies include enantioselective cyclizations, palladium-catalyzed cross-couplings, and late-stage functionalization to access stereodefined cyclopenta[b]benzofuran cores. Structure–activity relationship programs produced derivatives with varied substituents to optimize potency, solubility, and metabolic stability; these efforts have been reported in collaboration with contract research organizations and technology transfer offices at universities such as University of Cambridge and Imperial College London.

Safety, Toxicity, and Pharmacokinetics

Toxicological assessments in rodent and nonrodent species have evaluated acute and subchronic dosing, with safety pharmacology studies addressing cardiac, hepatic, and neurological endpoints in GLP settings at contract labs like Covance and Charles River Laboratories. Dose-limiting toxicities in animal studies included weight loss and reversible organ-specific effects; therapeutic indices were characterized relative to efficacious exposures. Pharmacokinetic profiling indicates hepatic metabolism with involvement of cytochrome P450 isoforms such as CYP3A4 analogues in preclinical species; plasma protein binding and tissue distribution studies were performed using LC–MS/MS platforms common to cores at UCL and University of Toronto.

Applications and Development Status

Current development focuses on oncology indications with potential expansion into cardioprotection and antiparasitic use. FL3 is of interest for combination regimens to overcome resistance to chemotherapy and targeted agents, and as a probe compound in chemical biology for studying translation control and mitochondrial regulation. Development partnerships and licensing discussions have been reported involving academic entrepreneurs and small biotechnology companies, but FL3 has not yet achieved regulatory approval or broad clinical deployment. Continued translational work by consortia including Wellcome Trust-funded groups and national research programs aims to clarify therapeutic windows and biomarker-driven patient selection strategies.

Category:Anticancer agents Category:Experimental drugs